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Abstract. A series of coumarin derivatives linked with 1,2,3-triazoles has been synthesized by utilizing the 
copper catalyzed azide-alkyne cycloaddition reaction and were screened for their antimicrobial and antioxidant 
properties. Some of the compounds displayed promising antibacterial activities (MIC ranging from 5-150 
µg/mL) and moderate antifungal activities as compared to the respective standards. The compounds 4k and 4g 
displayed good antibacterial activity when compared with the standard, Ciprofloxacin, and 4n exhibited better 
antifungal activity when compared to other synthesized compounds. The in silico docking studies of the active 
compounds were carried out against the gyrase enzyme and from those studies, it was acknowledged that 4k 
possessed significant hydrogen bonding and hydrophobic interactions which could be the plausible reason for 
its superior activity as compared to the other synthesized compounds. The compounds 4h and 4q showed 
promising antioxidant activity when compared with the standard, BHT, which could be attributed to the 
presence of electron donating substituents. 
Keywords: Coumarin; 1,2,3-triazole; click chemistry; antimicrobial; antioxidant. 
  
Resumen. Una serie de derivados de cumarina enlazados con 1,2,3-triazoles fue sintetizada empleando la 
reacción de cicloadición azida-alquino catalizada con cobre y fue evaluada en sus propiedades antimicrobianas 
y antioxidantes. Algunos de los compuestos exhibieron actividad antimicrobiana promisoria (intervalo MIC de 
5-150 µg/mL) y actividad antifúngica moderada con respecto a los estándares respectivos. Los compuestos 4g 
y 4k mostraron buena actividad antibacterial con relación al estándar. Fluconazole y 4n exhibieron mejor 
actividad antifúngica en comparación con el resto de los compuestos. Se llevaron a cabo estudios in silico de 
modelado molecular e interacción de los compuestos activos con la enzima girasa ADN. De estos estudios se 
observó que 4k posee enlaces puentes de hidrógeno e interacciones hidrofóbicas significativos, los cuales 
podrían ser una causa plausible de su actividad mayor a aquélla mostrada por los otros compuestos sintetizados. 
Los compuestos 4h y 4q mostraron una importante actividad antioxidante comparada con el estándar (BHT), 
lo cual podría atribuirse a la presencia de sustituyentes electro-donadores.   
Palabras clave: Cumarina; 1,2,3-triazol; reacciones click; antimicrobiano; antioxidante 
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Introduction 
    
The discovery of different types of microorganisms has explained the main reasons for various 
infectious diseases responsible for the most complex health issues of this century. Organisms like bacteria, 
fungi and viruses are identified to cause serious health hazards globally which may even lead to death [1]. 
Although a lot of drugs as potent antimicrobial agents have been identified hitherto, the rise of resistant 
microorganisms or the development of multi drug resistance in pathogens still remain as a major concern 
worldwide [2]. Hence, the discovery of new drugs with potent anti-microbial activity, particularly against the 
resistant strains is therefore highly needed to solve this problem [3]. Highly reactive free radicals and oxygen 
species that are present in the biological systems may abstract hydrogen atom from membrane, lipid, protein, 
DNA etc. and consequently lead to damages of several biological species and hence can initiate numerous 
degenerative diseases [4]. The impairments caused by free radicals can lead to aging, cancer, atherosclerosis 
and some other serious disorders. Therefore, the removal of free radicals from biological system is very 
important for the sustainability of cellular machinery and for preventing the commencement and propagation 
of oxidative diseases [5]. The supplementation of antioxidants (Free radical scavengers) is found to be beneficial 
for avoiding oxidative damages as they have the ability to trap free radical species. 
Coumarins are an important class of benzopyrones found in green plants either in free or combined 
state and display wide spectrum pharmacological activities [6]. Natural coumarins and their derivatives are of 
great interest due to their widespread biological properties and have attracted many medicinal chemists for 
further derivatization and screening them as novel therapeutic agents. Coumarins are reported to be active as 
antibacterial [7], anti-inflammatory [8] and antiviral agents [9] and the various therapeutic applications of 
coumarin derivatives include photo chemotherapy, anti-tumor therapy and anti-HIV therapy [10]. The coumarin 
motif is present within the chemical structure of pharmaceutical drugs such as warfarin, acenocoumarol, 
carbochromen etc. and in antibiotics such as novobiocin, clorobiocin and coumermycin A1 [11,12]. In view of 
these interesting pharmacological properties, the exploration of natural or synthetic coumarin derivatives has 
intrigued chemists for decades for their applicability as drugs. On the other hand, 1,2,3-triazoles are found in 
diverse bioactive compounds and have shown numerous biological potentials like anticancer [13], 
immunosuppressant [14], antimicrobial [15], antiviral [16], antiallergic [17] and anti-inflammatory activities 
[18]. The exceptional properties of 1,2,3-triazoles include high dipole character and hydrogen bonding 
capability and hence can be used as linkers of various molecules. Furthermore, these compounds are highly 
rigid and stable under acid/base hydrolysis and oxidative/reductive conditions which makes it a metabolically 
stable heterocyclic ring [19,20]. Several 1,2,3-triazole containing drug molecules are now available in the 
market (Fig 1) or is in the clinical trials of final stage [21]. 
 
Fig 1. Some of the available drugs containing 1,2,3-triazole moiety. 
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Nowadays, the microwave-assisted organic synthesis (MAOS) is rapidly becoming recognized as a 
valuable tool for facilitating a wide variety of transformations and hence has significantly extended its scope in 
drug discovery laboratories [22]. It is well documented that the microwave assistance can lead to remarkable 
rate enhancement with better reproducibility and less side reactions as compared to standard heating 
methodologies [23]. In the design and development of new drugs, the employment of molecular hybridization 
strategy which involves the combination of different pharmacophores may lead to compounds with interesting 
biological profiles. These combined chemical entities recognized and derived from known bioactive molecules 
possessing different mechanisms of action could be beneficial for various treatments as they possibly offer 
some advantages in overcoming drug resistance as well as improving their biological potency [24,25]. 
Since the combination of two pharmacophores on the same scaffold is a well established approach to 
more potent drugs [24-27], we focused our attention in the synthesis of some pharmacologically relevant 
coumarin derivatives containing 1,2,3-triazole moiety. Owing to the instability of coumarin nuclei in basic as 
well as prolonged heating conditions and as a continuation of our ongoing research in the synthesis of some 
biologically active molecules [28-31], it has been planned to utilize the copper catalyzed Huigsen 1,3 dipolar 
cycloaddition, commonly known as click chemistry, for the synthesis of various coumarin analogues under 
microwave irradiation. The synthesis and biological evaluation of 1,2,3-triazole derivatives linked with 
coumarin moiety by utilizing copper catalyzed azide–alkyne cycloaddition is recently reported in the literature 
by various research groups [32-35]. However, most of these results were limited to the usage of aromatic azides 
and a very few benzylic azides, and the reaction times are generally very high (18-24 h) that may lead to various 
side-products. Moreover, the scope of diverse aliphatic, acyclic and cyclic azides in this area is relatively 
unexplored and challenging as it is difficult to handle aliphatic azides. Furthermore, aliphatic azides are less 
reactive and extremely stable in almost all the reaction media and hence it requires prolonged reaction times for 
complete conversion of starting materials to products. These observations prompted us to optimize the planned 
synthetic methodology under microwave irradiation as it will be less time consuming and highly efficient with 
less side products. In this paper, we report a facile, convenient and rapid access for the microwave irradiated 
synthesis of a series of coumarins linked with 1,2,3-triazoles. The synthesized compounds were screened for 
their antimicrobial and antioxidant potencies, and the in-silico docking studies of selected compounds against 
gyrase enzyme has been subsequently investigated. 
 
 
Experimental 
 
Chemistry 
General 
All solvents and reagents were obtained from commercial suppliers and used without any further 
purification unless otherwise noted. Microwave reactions were performed in a single mode Biotage Initiator 
Microwave Synthesizer and temperature was monitored using infrared. Analytical TLC was performed on pre-
coated aluminum sheets of silica (60 F 254 nm) and visualized by short-wave UV light at λ 254. Melting points 
were determined on an EZ - Melt automated melting point apparatus. 1H NMR (400 or 300 MHz) and 13C NMR 
(100 or 75 MHz) were recorded on Bruker Avance II spectrometer and chemical shifts were measured in δ 
(ppm). The following abbreviations are used for the splitting patterns: s for singlet, d for doublet, t for triplet, 
m for multiplet and br for broad. LC-MS analyses were performed using ESI/APCI, with an ATLANTIS C18 
(50 X 4.6 mm-5µm) column and a flow rate of 1.2 mL/min. 
 
Procedure for the synthesis of 4-methyl-7-hydroxy coumarin intermediate (2) 
To the weighed quantity of resorcinol (1 equiv.) and ethyl acetoacetate (1.1 equiv.), the ionic liquid 
[bmim]Cl·2AlCl3 (1.1 equiv.) was added and the reaction mixture was stirred at 30 °C for 20 min. All additions 
were carried out in an inert atmosphere. The reaction was quenched by adding 6 M HCl in cold conditions. The 
resultant product was filtered and further purified by column chromatography to obtain the titled compound 2 
as off white solid in 88 % yield. mp: 180-182 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.34 (s, 3H, CH3), 6.10 (s, 
1H, ArH), 6.69 (d, J=2.3 Hz, 1H, ArH), 6.78 (dd, J=8.7, 2.3 Hz, 1H, ArH), 7.56 (d, J=8.7 Hz, 1H, ArH), 10.48 
(bs, 1H, OH). 13C NMR (100 MHz, DMSO-d6): δ 18.0, 102.1, 110.2, 112.0, 112.8, 126.5, 153.5, 154.8, 160.2, 
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161.1. LC-MS: Calculated 176.2, Observed 177.2. Analysis calcd for C10H8O3: C, 68.18, H, 4.58, O, 27.25 %, 
found: C, 68.21, H, 4.57, O, 27.22 %. 
 
Procedure for the synthesis of 4-methyl-7-(prop-2-ynyloxy)-2H-chromen-2-one intermediate 
(3) 
To the weighed quantity of 4-methyl-7-hydroxy coumarin 2 (1 equiv.) in acetone, were added K2CO3 
(3 equiv.) and propargyl bromide (1.2 equiv.) in inert atmosphere and the reaction mixture was stirred at RT 
for 12 hours. The reaction completion was monitored by TLC and the mixture was poured into ice-cold water 
with severe stirring. The solution was extracted with ethyl acetate, separated the organic layer, washed with 
brine, dried with Na2SO4 and distilled under reduced pressure to obtain the titled compound as brown solid in 
93 % yield. mp: 139-141 °C; 1H NMR (400 MHz, CDCl3): δ 2.40 (s, 3H, CH3), 2.57 (s, 1H, CH), 4.76 (d, J=2.3 
Hz, 2H, OCH2), 6.16 (s, 1H, ArH), 6.92 (d, J = 2.4, 1H, ArH), 6.94 (s, 1H, ArH), 7.52 (d, J = 9.2 Hz, 1H, ArH). 
13C NMR (100 MHz, CDCl3): δ 18.7, 56.3, 76.6, 77.6, 102.3, 112.5, 112.8, 114.4, 125.7, 152.5, 155.1, 160.5, 
161.2. LC-MS: Calculated 214.2, Observed 215.2. Analysis calcd for C13H10O3: C, 72.89, H, 4.71, O, 22.41 %, 
found: C, 72.92, H, 4.70, O, 22.38 %. 
 
General procedure for the synthesis of compounds (4a-t)  
To the weighed quantity of intermediate 3 (1 equiv.) in t-butanol/water (1:1), were added azide (1.3 
equiv.), CuSO4.5H2O (0.1 equiv.) and sodium ascorbate (0.3 equiv.) and the reaction mixture was placed in the 
microwave and heated for 2–5 min. at 90 °C at 110 W power. The reaction mixture was quenched with water 
and extracted with DCM, dried in Na2SO4 and distilled in reduced pressure to obtain the crude product. The 
crude product was further purified by column chromatography and eluted in varying polarities to obtain the 
titled compounds 4a-t.  
 
7-((1-(2-Methoxycyclopentyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one (4a) 
White solid: mp 168-170 °C; 1H NMR (400 MHz, DMSO-d6): δ 1.62-1.67 (m, 1H, CH), 1.76-1.85 (m, 
2H, CH2), 1.96-2.09 (m, 2H, CH2), 2.23-2.28 (m, 1H, CH),  2.49 (d, J=1.7 Hz, 3H, CH3), 3.18 (s, 3H, OCH3), 
4.00-4.04 (m, 1H, OCH), 4.83-4.88 (m, 1H, NCH),  5.25 (s, 2H, OCH2), 6.22 (d, J=1.0 Hz, 1H, ArH), 7.02-
7.05 (dd, J=8.8, 2.5 Hz, 1H, ArH), 7.15 (d, J=2.4 Hz, 1H, ArH), 7.70 (d, J=8.8 Hz, 1H, ArH), 8.39 (s, 1H, ArH). 
13C NMR (100 MHz, DMSO-d6): δ 18.4, 23.5, 26.7, 33.5, 63.5, 65.7, 69.0, 76.1, 111.6, 113.7, 116.1, 124.9, 
128.5, 133.9, 146.6, 154.2, 157.0, 160.6, 160.6. LC-MS: Calculated 355.2, Observed 356.2. Analysis calcd for 
C19H21N3O4: C, 64.21, H, 5.96, N, 11.82 %, found: C, 64.26, H, 5.93, N, 11.81 %. 
 
7-((1-(2-Hydroxycyclohexyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one (4b).  
White solid: mp 167-169 °C; 1H NMR (400 MHz, DMSO-d6): δ 1.82-1.89 (m, 5H, CH), 1.95-1.97 (m, 
3H, CH), 2.49 (d, J=1.7 Hz, 3H, CH3), 3.71-3.73 (m, 1H, OCH), 4.21-4.24 (m, 1H, NCH), 4.95 (d, J=5.9 Hz, 
1H, OH), 5.23 (s, 2H, OCH2), 6.22 (d, J=0.9 Hz, 1H, ArH),  7.03-7.06 (dd, J=8.8, 2.4 Hz, 1H, ArH), 7.16 (d, 
J=2.4 Hz, 1H, ArH), 7.70 (d, J=8.8 Hz, 1H, ArH), 8.25 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.4, 
23.4, 24.7, 26.8, 33.5, 61.8, 69.7, 77.1, 112.7, 114.5, 115.8, 125.8, 128.2, 134.0, 147.9, 154.6, 157.6, 160.7, 
161.0. LC-MS: Calculated 355.2, Observed 356.2. Analysis calcd for C19H21N3O4: C, 64.21, H, 5.96, N, 
11.82 %, found: C, 64.25, H, 5.92, N, 11.81 %. 
 
7-((1-(2-Hydroxycyclopentyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one 
(4c).  
White solid: mp 155-157 °C; 1H NMR (300 MHz, DMSO-d6): δ 1.96-2.02  (m, 3H, CH), 2.18-2.23 
(m, 2H, CH2), 2.25-2.30 (m, 1H, CH2), 2.49 (d, J=1.7 Hz, 3H, CH3), 4.19-4.27 (m, 1H, OCH), 4.58-4.66 (m, 
1H, NCH), 5.23 (s, 2H, OCH2), 5.23 (d, J=3.45 Hz, 1H, OH), 6.21 (s, 1H, ArH), 7.01-7.05 (dd, J=8.8, 2.5 Hz, 
1H, ArH), 7.15 (d, J=2.5 Hz, 1H, ArH), 7.70 (d, J=8.8 Hz, 1H, ArH), 8.32 (s, 1H, ArH). 13C NMR (75 MHz, 
DMSO-d6): δ 18.4, 23.4, 26.8, 33.5, 63.8, 69.4, 76.2, 111.9, 113.8, 116.1, 125.8, 128.5, 133.9, 147.7, 154.7, 
157.6, 160.8, 160.9. LC-MS: Calculated 341.2, Observed 342.2. Analysis calcd for C18H19N3O4: C, 63.33, H, 
5.61, N, 12.31 %, found: C, 63.37, H, 5.59, N, 12.30 %. 
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7-((1-(2-(2-Phenoxycyclohexyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one 
(4d).  
White solid: mp 193-195 °C; 1H NMR (400 MHz, DMSO-d6): δ 1.72-1.84 (m, 3H, CH), 1.89-1.93 (m, 
2H, CH2), 1.99-2.03 (m, 1H, CH), 2.08-2.14 (m, 2H, CH2), 2.46 (d, J=1.2 Hz, 3H, CH3), 3.78-3.84 (m, 1H, 
OCH), 4.28-4.37 (m, 1H, NCH), 5.28 (s, 2H, OCH2), 6.24 (d, J=1.1 Hz, 1H, ArH), 7.04-7.07 (dd, J=8.2, 2.0 
Hz, 1H, ArH), 7.09-7.18 (m, 3H, ArH), 7.17 (d, J=2.5 Hz, 1H, ArH), 7.26-7.41 (m, 2H, ArH), 7.67 (d, J=8.1 
Hz, 1H, ArH), 8.39 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.4, 23.4, 24.7, 26.8, 33.5, 64.7, 70.0, 
78.1, 112.7, 114.5, 115.8, 118.1, 118.6, 119.2, 125.8, 127.3, 128.2, 129.5, 134.0, 147.9, 154.6, 157.6, 161.8, 
160.7, 160.9. LC-MS: Calculated 431.2, Observed 432.2. Analysis calcd for C25H25N3O4: C, 69.59, H, 5.84, N, 
9.74 %, found: C, 69.64, H, 5.83, N, 9.72 %. 
 
7-((1-(2-(2-Phenoxycyclopentyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one 
(4e). 
White solid: mp 189-191 °C; 1H NMR (400 MHz, DMSO-d6): δ 1.62-1.69 (m, 1H, CH), 1.74-1.86 (m, 
2H, CH2), 1.95-2.02 (m, 2H, CH2), 2.17-2.28 (m, 1H, CH), 2.40 (d, J=1.1 Hz, 3H, CH3), 4.27 (q, J=1.6 Hz, 1H, 
OCH), 4.63 (dt, J=2.3, 1.4 Hz, 1H, NCH), 5.26 (s, 2H, OCH2), 6.28 (d, J=1.2 Hz, 1H, ArH), 7.02-7.04 (dd, 
J=8.3, 2.1 Hz, 1H, ArH), 7.10-7.19 (m, 3H, ArH), 7.16 (d, J=2.4 Hz, 1H, ArH), 7.27-7.40 (m, 2H, ArH), 7.68 
(d, J=8.2 Hz, 1H, ArH),  8.31 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.4, 23.6, 26.8, 33.5, 63.8, 
69.7, 75.9, 111.7, 114.9, 116.2, 119.7, 124.8, 125.8, 126.3, 127.7, 128.6, 129.9, 133.8, 147.6, 154.7, 157.4, 
159.9, 160.8, 161.2. LC-MS: Calculated 417.2, Observed 418.2. Analysis calcd for C24H23N3O4: C, 69.05, H, 
5.55, N, 10.07 %, found: C, 69.08, H, 5.55, N, 10.06 %. 
 
7-((1-(2-(2-Chloropyridin-3-yloxy)cyclohexyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-
chromen-2-one (4f).  
Light yellow solid: mp 180-182 °C; 1H NMR (400 MHz, DMSO-d6): δ 1.70-1.81 (m, 3H, CH), 1.85-
1.90 (m, 2H, CH2), 1.95-2.01 (m, 1H, CH), 2.08-2.16 (m, 2H, CH2), 2.45 (d, J=1.1 Hz, 3H, CH3), 3.75-3.82 (m, 
1H, OCH), 4.27-4.33 (m, 1H, NCH), 5.27 (s, 2H, OCH2), 6.26 (d, J=1.2 Hz, 1H, ArH), 7.04-7.07 (dd, J=8.2, 
1.6 Hz, 1H, ArH), 7.17 (d, J=2.3 Hz, 1H, ArH), 7.41 (d, J=8.0 Hz, 1H, ArH), 7.67 (d, J=8.3 Hz, 1H, ArH), 8.13 
(d, J=8.4 Hz, 1H, ArH), 8.39 (s, 1H, ArH), 8.67 (d, J=8.5 Hz, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 
18.4, 23.5, 24.6, 25.9, 32.9, 64.6, 69.0, 77.7, 112.5, 114.4, 115.9, 125.8, 127.4,  128.9, 129.6, 133.8, 145.5, 
146.5, 147.9, 154.6, 157.6, 159.8, 160.8, 161.2. LC-MS: Calculated 466.2, Observed 467.2. Analysis calcd for 
C24H23ClN4O4: C, 61.74, H, 4.97, N, 12.00 %, found: C, 61.78, H, 4.95, N, 11.99 %. 
 
7-((1-(2-(2-Chloropyridin-3-yloxy)cyclopentyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-
chromen-2-one (4g). 
Light yellow solid: mp 203-205 °C; 1H NMR (400 MHz, DMSO-d6): δ 1.90-1.97 (m, 3H, CH), 2.33-
2.38 (m, 3H, CH), 2.49 (d, J=1.7 Hz, 3H, CH3), 5.18-5.22 (m, 2H, NCH, OCH), 5.25 (s, 2H, OCH2), 6.21 (d, 
J=1.0 Hz, 1H, ArH), 7.00-7.03 (dd, J=8.8, 2.4 Hz, 1H, ArH), 7.13 (d, J=2.4 Hz, 1H, ArH), 7.29-7.32 (m, 1H, 
ArH), 7.47-7.49 (dd, J=8.2, 1.3 Hz, 1H, ArH), 7.68 (d, J=8.8 Hz, 1H, ArH), 7.95-7.96 (dd, J=4.6, 1.4 Hz, 1H, 
ArH),  8.41 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.4, 23.6, 26.8, 33.5, 63.8, 69.7, 75.9,  111.7, 
114.9, 116.2, 126.3, 127.9, 128.6, 129.6, 133.8, 145.7, 147.6, 149.6, 154.7, 157.7, 159.9,  160.9, 161.2. LC-
MS: Calculated 452.0, Observed 453.0. Analysis calcd for C23H21ClN4O4: C, 61.00, H, 4.67, N, 12.37 %, found: 
C, 61.03, H, 4.65, N 12.35 %. 
 
7-((1-(4-Hydroxypyrrolidin-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one 
(4h).  
Yellow solid: mp 146-148 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.39 (d, J=1.2 Hz, 3H, CH3), 3.55-
3.76 (m, 1H, CH), 3.79-3.89 (m, 1H, CH), 3.92-4.00 (m, 2H, CH2), 5.24 (d, J=1.8 Hz, 1H, OCH), 5.31 (s, 2H, 
OCH2), 5.39 (d, J=1.0 Hz, 1H, NCH), 5.60 (d, J=1.2 Hz, 1H, OH), 6.23 (d, J=1.0 Hz, 1H, ArH), 7.03-7.06 (dd, 
J=8.2, 1.5 Hz, 1H, ArH), 7.16 (d, J=2.4 Hz, 1H, ArH), 7.70 (d, J=8.2 Hz, 1H, ArH), 8.55 (s, 1H, ArH), 9.72 
(bs, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ 18.8, 44.3, 53.2, 64.8, 69.4, 77.4, 111.9, 113.7, 116.3, 125.7, 
129.4, 133.6, 146.9, 154.7, 157.6, 160.6, 160.8. LC-MS: Calculated 342.0, Observed 343.0. Analysis calcd for 
C17H18N4O4: C, 59.64, H, 5.30, N, 16.37 %, found: C, 59.71, H, 5.26, N, 16.36 %. 
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7-((1-(4-Phenoxypyrrolidin-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one 
(4i).  
Light yellow solid: mp 190-192 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.49 (d, J=1.6 Hz, 3H, CH3), 
3.55-3.60 (m, 1H, CH), 3.76-3.79 (m, 1H, CH), 3.89-3.96 (m, 2H, CH), 5.31 (s, 2H, OCH2), 5.40 (d, J=4.0 Hz, 
1H, OCH), 5.61 (d, J=4.8 Hz, 1H, NCH), 6.23 (d, J=0.9 Hz, 1H, ArH), 7.00-7.05 (m, 4H, ArH), 7.17 (d, J=2.4 
Hz, 1H, ArH), 7.32-7.36 (m, 2H, ArH), 7.71 (d, J=8.8 Hz, 1H, ArH), 8.55 (s, 1H, ArH), 9.72 (bs, 1H, NH). 13C 
NMR (100 MHz, DMSO-d6): δ 18.8, 44.3, 53.2, 64.8, 69.4, 77.4, 111.9, 113.7, 116.3, 119.2, 120.3, 122.5, 
125.7, 127.8, 128.6, 129.4, 133.6, 146.9, 154.7, 157.6, 158.8, 159.9, 160.8. LC-MS: Calculated 418.2, Observed 
419.2. Analysis calcd for C23H22N4O4: C, 66.02, H, 5.30, N, 13.39 %, found: C, 66.05, H, 5.29, N, 13.39 %. 
 
7-((1-Benzyl-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one [32] (4j).  
White solid: mp 118-120 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.49 (d, J=1.2 Hz, 3H, CH3), 4.98 (s, 
2H, NCH2), 5.25 (s, 2H, OCH2), 6.24 (d, J=1.2 Hz, 1H, ArH), 7.09-7.11 (dd, J=8.2, 1.6 Hz, 1H, ArH), 7.16-
7.19 (dd, J=8.6, 2.1 Hz, 2H, ArH), 7.21 (d, J=2.2 Hz, 1H, ArH), 7.36 (m, 1H, ArH), 7.69-7.71 (dd, J=8.7, 1.92 
Hz, 2H, ArH), 7.73 (d, J=7.3 Hz, 1H, ArH), 8.47 (s, 1H, ArH. 13C NMR (100 MHz, DMSO-d6): δ 18.8, 59.5, 
76.8, 112.4, 114.5, 116.5, 125.8, 126.7, 128.6, 129.1, 131.6, 134.6, 143.5, 148.9, 154.5, 156.9, 159.3, 160.5. 
LC-MS: Calculated 347.0, Observed 348.0. Analysis calcd for C20H17N3O3: C, 69.15, H, 4.93, N, 12.10 %, 
found: C, 69.20, H, 4.91, N, 12.09 %. 
 
7-((1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one (4k). 
Off white solid: mp 175-177 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.47 (d, J=1.1 Hz, 3H, CH3), 4.97 
(s, 2H, NCH2), 5.24 (s, 2H, OCH2), 6.22 (d, J=1.0 Hz, 1H, ArH), 7.01-7.04 (dd, J=7.8, 1.8 Hz, 2H, ArH), 7.11-
7.14 (dd, J1=7.9, 1.9 Hz, 1H, ArH), 7.21 (d, J=2.5 Hz, 1H, ArH),  7.55-7.57 (dd, J=8.2, 2.2 Hz, 2H, ArH), 7.70 
(d, J=7.4 Hz, 1H, ArH), 8.51 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.8, 59.5, 76.8, 112.4, 114.5, 
115.5 & 115.7 (d, 2JCF =21 Hz), 116.5, 125.8, 128.6, 129.7 & 129.8 (d, 3JCF =8 Hz), 134.6, 142.8, 148.9, 156.9, 
158.3 & 160.7 (d, 1JCF =241.70 Hz), 161.3, 162.5. LC-MS: Calculated 365.0, Observed 366.0. Analysis calcd 
for C20H17N3O3: C, 65.75, H, 4.41, N, 11.50 %, found: C, 65.79, H, 4.38, N, 11.51 %. 
 
7-((1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one [33] (4l). 
White solid: mp 162-163 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.46 (d, J=1.2 Hz, 3H, CH3), 4.95 (s, 
2H, NCH2), 5.21 (s, 2H, OCH2), 6.24 (d, J=1.3 Hz, 1H, ArH), 7.03 (dd, J=7.6, 1.4 Hz, 1H, ArH), 7.10-7.13 (dd, 
J=7.8, 1.8 Hz, 2H, ArH), 7.29 (d, J=2.6 Hz, 1H, ArH), 7.48-7.51 (dd, J=8.1, 2.1 Hz, 2H, ArH), 7.73 (d, J=7.6 
Hz, 1H, ArH), 8.43 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.7, 59.7, 76.8, 112.4, 114.5, 116.5, 
125.8, 128.6, 129.0, 131.3, 134.6, 138.8, 143.7, 148.9, 154.5, 155.7, 158.2, 160.4. LC-MS: Calculated 381.1, 
Observed 382.1. Analysis calcd for C20H16ClN3O3: C, 62.91, H, 4.22, N, 11.01 %, found: C, 62.95, H, 4.21, N, 
10.99 %. 
 
4-((4-((4-Methyl-2-oxo-2H-chromen-7-yloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)benzonitrile 
(4m).  
White solid: mp 175-177 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.51 (d, J=1.1 Hz, 3H, CH3), 4.99 (s, 
2H, NCH2), 5.29 (s, 2H, OCH2), 6.33 (d, J=1.4 Hz, 1H, ArH), 7.01-7.04 (dd, J=7.6, 1.2 Hz, 1H, ArH), 7.09-
7.12 (dd, J=8.0, 2.0 Hz, 2H, ArH), 7.28 (d, J=2.7 Hz, 1H, ArH), 7.41-7.44 (dd, J=8.4, 2.0 Hz, 2H, ArH), 7.77 
(d, J=7.6 Hz, 1H, ArH), 8.50 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.7, 58.9, 76.8, 110.2, 112.4, 
114.5, 116.5, 118.2, 125.8, 128.6, 128.8, 130.6, 134.6, 142.9, 148.9, 154.5, 156.8, 158.6, 161.1. LC-MS: 
Calculated 372.1, Observed 373.1. Analysis calcd for C21H16N4O3: C, 67.73, H, 4.33, N, 15.05 %, found: C, 
67.78, H, 4.31, N, 15.04 %. 
 
7-((1-(4-Nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one [32] (4n).  
Light yellow solid: mp 144-146°C; 1H NMR (400 MHz, DMSO-d6): δ 2.49 (d, J=1.4 Hz, 3H, CH3), 
4.97 (s, 2H, NCH2), 5.26 (s, 2H, OCH2), 6.21 (d, J=1.5 Hz, 1H, ArH), 6.96-6.99 (dd, J=7.4, 1.3 Hz, 1H, ArH), 
7.07-7.09 (dd, J=8.0, 1.8 Hz, 2H, ArH), 7.26 (d, J=2.8 Hz, 1H, ArH), 7.37-7.40 (dd, J=8.1, 1.9 Hz, 2H, ArH), 
7.68 (d, J=7.5 Hz, 1H, ArH), 8.46 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.7, 59.4, 76.8, 112.4, 
114.5, 116.5, 124.9 (2 peaks), 125.8, 128.6, 130.8 (2 peaks), 134.6, 142.9, 146.8, 148.9, 154.5, 156.8, 158.5, 
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160.9. LC-MS: Calculated 392.1, Observed 393.1. Analysis calcd for C20H16N4O5: C, 61.22, H, 4.11, N, 
14.28 %, found: C, 61.27, H, 4.08, N, 14.26 %. 
 
7-((1-(4-Hydroxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one (4o).  
Light brown solid: mp 144-146 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.46 (d, J=1.1 Hz, 3H, CH3), 
4.93 (s, 2H, NCH2), 5.19 (s, 2H, OCH2), 6.24 (d, J=1.3 Hz, 1H, ArH), 6.94-6.97 (dd, J=7.3, 1.4 Hz, 1H, ArH), 
7.07-7.10 (dd, J=7.6, 1.5 Hz, 2H, ArH), 7.28 (d, J=2.4 Hz, 1H, ArH), 7.36-7.39 (dd, J=8.0, 1.9 Hz, 2H, ArH), 
7.68 (d, J=7.4 Hz, 1H, ArH), 8.57 (s, 1H, ArH), 10.67 (bs, 1H, OH). 13C NMR (100 MHz, DMSO-d6): δ 18.8, 
59.4, 76.8, 112.4, 114.5, 116.5, 117.5 (2 peaks), 125.8, 128.6, 131.1 (2 peaks), 133.4, 134.6, 148.9, 154.5, 155.8, 
157.0, 160.3, 161.0. LC-MS: Calculated 363.1, Observed 364.1. Analysis calcd for C20H17N3O4: C, 66.11, H, 
4.72, N, 11.56 %, found: C, 66.17, H, 4.69, N, 11.55 %. 
 
7-((1-(4-Methoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one (4p).  
Off white solid: mp 178-180 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.51 (d, J=1.0 Hz, 3H, CH3), 3.45 
(s, 3H, OCH3), 4.99 (s, 2H, NCH2), 5.29 (s, 2H, OCH2), 6.33 (d, J=1.3 Hz, 1H, ArH), 7.01-7.04 (dd, J=7.6, 1.7 
Hz, 1H, ArH), 7.09-7.12 (dd, J=7.8, 2.0 Hz, 2H, ArH), 7.28 (d, J=2.2 Hz, 1H, ArH), 7.41-7.43 (dd, J=8.1, 2.0 
Hz, 2H, ArH), 7.77 (d, J=7.4 Hz, 1H, ArH), 8.50 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.7, 58.5, 
66.6, 76.9, 112.9, 114.7, 116.0, 116.3 (2 peaks), 125.8, 128.6, 130.6 (2 peaks), 133.0, 134.3, 146.4, 148.7, 155.0, 
157.0, 160.7, 161.0. LC-MS: Calculated 377.1, Observed 378.1. Analysis calcd for C21H19N3O4: C, 66.83, H, 
5.07, N, 11.13 %, found: C, 66.87, H, 5.05, N, 11.11 %. 
 
7-((1-(4-Aminobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one (4q).  
Yellow solid: mp 173-175 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.46 (d, J=1.2 Hz, 3H, CH3), 4.95 
(s, 2H, NCH2), 5.21 (s, 2H, OCH2), 5.88 (bs, 2H, NH2), 6.24 (d, J=1.4 Hz, 1H, ArH), 7.03-7.05 (dd, J=7.2, 1.5 
Hz, 1H, ArH), 7.10-7.13 (dd, J=7.5, 1.8 Hz, 2H, ArH), 7.29 (d, J=2.4 Hz, 1H, ArH), 7.48-7.51 (dd, J=7.8, 2.0 
Hz, 2H, ArH), 7.73 (d, J=7.8 Hz, 1H, ArH), 8.43 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.8, 59.4, 
76.8, 112.4, 114.5, 116.5, 117.5 (2 peaks), 125.8, 128.6, 129.8, 131.1 (2 peaks), 134.6, 148.9, 154.5, 155.8, 
157.0, 160.3, 161.0. LC-MS: Calculated 362.1, Observed 363.1. Analysis calcd for C20H18N4O3: C, 66.29, H, 
5.01, N, 15.46  %, found: C, 66.32, H, 5.00, N, 15.44 %. 
 
7-((1-(4-(Methylamino)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one 
(4r).  
Off white solid: mp 177-179 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.51 (d, J=1.2 Hz, 3H, CH3), 3.02 
(s, 3H, NCH3), 4.99 (s, 2H, NCH2), 5.29 (s, 2H, OCH2), 6.33 (d, J=1.2 Hz, 1H, ArH), 7.01-7.04 (dd, J=7.2, 1.3 
Hz, 1H, ArH), 7.09-12 (dd, J=7.5, 1.8 Hz, 2H, ArH), 7.28 (d, J=2.7 Hz, 1H, ArH), 7.41-7.43 (dd, J=8.1, 2.2 
Hz, 2H, ArH), 7.77 (d, J=7.4 Hz, 1H, ArH), 7.84 (bs, 1H, NH), 8.53 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-
d6): δ 18.6, 38.4, 59.1, 76.2, 111.9, 114.3, 116.1, 117.5 (2 peaks), 126.2, 128.2, 129.7, 130.8 (2 peaks), 134.1, 
147.9, 154.1, 155.7, 156.9, 159.1, 160.9. LC-MS: Calculated 376.2, Observed 377.2. Analysis calcd for 
C21H20N4O3: C, 67.01, H, 5.36, N, 14.88 %, found: C, 67.06, H, 5.34, N, 14.87 %. 
 
4-Methyl-7-((1-(4-methyl-benzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (4s). 
 White solid: mp 171-173 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.33 (s, 3H, CH3), 2.46 (d, J=1.4 Hz, 
3H, CH3), 4.93 (s, 2H, NCH2), 5.19 (s, 2H, OCH2), 6.24 (d, J=1.3 Hz, 1H, ArH), 6.94-6.97 (dd, J=7.5, 1.3 Hz, 
1H, ArH), 7.07-7.09 (dd, J=7.8, 1.7 Hz, 2H, ArH), 7.28 (d, J=2.5 Hz, 1H, ArH), 7.36-7.39 (dd, J=8.1, 1.88 Hz, 
2H, ArH), 7.68 (d, J=7.4 Hz, 1H, ArH), 8.57 (s, 1H, ArH). 13C NMR (100 MHz, DMSO-d6): δ 18.3, 26.8, 58.7, 
76.8, 112.4, 114.5, 116.5, 125.8, 128.1, 128.6 (2 peaks), 130.1 (2 peaks), 134.6, 135.4, 136.3, 148.9, 154.5, 
156.9, 159.3, 160.5. LC-MS: Calculated 361.0, Observed 362.0. Analysis calcd for C21H19N3O3: C, 69.79, H, 
5.30, N, 11.63 %, found: C, 69.84, H, 5.29, N, 11.61 %. 
 
 
7-((1-(4-Ethylbenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one (4t).  
White solid: mp 175-177 °C; 1H NMR (400 MHz, DMSO-d6): δ 2.31 (t, J=4.5 Hz, 3H, CH3), 2.44 (d, 
J=1.2 Hz, 3H, CH3), 4.90 (s, 2H, NCH2), 5.06 (q, J=4.7 Hz, 2H, CH2), 5.19 (s, 2H, OCH2), 6.24 (d, J=1.3 Hz, 
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1H, ArH), 6.90-6.93 (dd, J=7.3, 1.2 Hz, 1H, ArH), 7.05-7.08 (dd, J=7.7, 1.6 Hz, 2H, ArH), 7.21 (d, J=2.6 Hz, 
1H, ArH), 7.37-7.40 (dd, J=8.0, 1.8 Hz, 2H, ArH), 7.66 (d, J=7.5 Hz, 1H, ArH), 8.53 (s, 1H, ArH). 13C NMR 
(100 MHz, DMSO-d6): δ 18.9, 19.0, 31.1, 58.1, 76.6, 112.3, 115.3, 116.4, 126.1, 128.3, 128.4 (2 peaks), 129.9 
(2 peaks), 133.9, 135.0, 135.8, 148.0, 154.3, 155.8, 159.7, 160.9. LC-MS: Calculated 375.2, Observed 376.2. 
Analysis calcd for C22H21N3O3: C, 70.38, H, 5.64, N, 11.19 %, found: C, 70.43, H, 5.63, N, 11.16 %. 
 
Biology 
The experimental procedure for the determination of biological activities is detailed in the Supporting 
Information. 
 
In silico studies 
An entirely in-house developed drug discovery informatics system OSIRIS was used to perform 
ADMET based calculations. It is a Java based library layer that provides reusable cheminformatics functionality 
and was used to predict the toxicity risks and overall drug score via in silico [52]. The structure of synthesized 
molecules and the standards were drawn in ChemBioDraw tool (ChemBioOffice Ultra 14.0 suite) assigned with 
proper 2D orientation and structure of each one was checked for structural drawing error. Energy of each 
molecule was minimized using ChemBio3D (ChemBioOffice Ultra 14.0 suite). The energy minimized ligand 
molecules were then used as input for AutoDockVina, in order to carry out the docking simulation [53]. The 
protein databank (PDB) coordinate file entitled ‘2XCT.pdb’ was used as receptor (protein) molecule which is 
a structure of S. aureus gyrase in complex with Ciprofloxacin and DNA [54]. All the water molecules were 
removed from the receptor and SPDBV DeepView was used to automatically rebuild the missing side chains 
in the receptor. The Graphical User Interface program ‘MGL Tools’ was used to set the grid box for docking 
simulations. The grid was set so that it surrounds the region of interest (active site) in the macromolecule. 
In the present study, the active site was selected based on the amino acid residues of 2XCT, which are 
involved in binding with Ciprofloxacin. Therefore, the grid was centered at the region including the 2 amino 
acid residues (Arg 458 and Gly 459) and 4 nitrogenous bases from DNA that is 
guanine (G), adenine (A), thymine (T) or cytosine (C) as evidenced by the work of Bax et al., 2010 [55]. This 
surrounds the active site. The grid box volume was set to 8, 14, and 14 Å for x, y and z dimensions respectively, 
and the grid center was set to 3.194, 43.143 and 69.977 for x, y and z center respectively, which covered the 2 
amino acid residues and 4 nitrogenous bases in the considered active pocket. AutoGrid 4.0 Program supplied 
with AutoDock 4.0 was used to produce grid maps [55]. The docking algorithm provided with AutoDockVina 
was used to search for the best docked conformation between ligand and protein. During the docking process, 
a maximum of 100 conformers was considered for each ligand. All the AutoDock docking runs were performed 
in Core i7 Intel processor CPU with 8 GB DDR3l RAM. AutoDockVina was compiled and run under Windows 
8.0 professional operating system. LigPlot+ [56] and PyMol [51] were used to deduce the pictorial 
representation of interaction between the ligands and the target protein. 
 
 
Results and discussion 
 
Chemistry 
As depicted in Schemes 1 and 2, we started our synthetic strategy by the synthesis of parent 4-methyl-
7-hydroxy coumarin 2 by the modified Pechmann cyclization reaction in which resorcinol 1 was treated with 
ethyl acetoacetate in 1-butyl-3-methylimidazolium chloro aluminate at 30 °C for 20 minutes [36]. The obtained 
4-methyl-7-hydroxy coumarin intermediate 2 was then treated with propargyl bromide in K2CO3 to procure the 
O-propargylated product 3. The alkyne intermediate 3 thus obtained was further subjected to the copper 
catalyzed 1,3 dipolar cycloaddition reaction with various azides under microwave irradiation at 90 °C with the 
intention of synthesizing an array of coumarin derivatives with potent antimicrobial and antioxidant properties. 
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Scheme 1. Synthesis of 4-methyl-7-propargylated coumarin intermediate. 
 
 
 
 
RN3
Na-Ascorbate
CuSO4.5H2O
OO O
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N
N
N
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Microwave, 90oC
O OO
3
t-BuOH-H2O (1:1)
2-5 min.  
Scheme 2. Synthesis of coumarins linked with 1,2,3-triazoles. 
 
 
 
As a model substrate, we started our initial screening by treating the alkyne intermediate 3 with 2-
methoxy cyclopentyl azide in sodium ascorbate and hydrated copper sulfate (CuSO4.5H2O) at 90 °C in 
microwave. The solvent system used for the reaction optimization was an equimolar mixture of t-butanol and 
water. To our delight, we identified the reaction completion within 5 min. by TLC and further analysis and 
purification procured the expected product in 100 % yield (LC-MS) with 97 % isolated yield. In order to validate 
the predominance of microwave irradiation, we carried out the same reaction at room temperature as well as 
standard thermal conditions (Table 1, Entry 1). The reaction took 6 h. for completion under conventional heating 
with 80 % yield while it required 18 h. under ambient temperature and the yield of the product was found to be 
86 %.  
With the promising results in hand, our next attention was to explore the generality of this synthetic 
methodology. Keeping this in mind, we treated the intermediate 3 with a series of aliphatic azides under 
microwave irradiation. Gratifyingly, all the azides reacted efficiently to render the 1,2,3-triazoles linked with 
coumarins in excellent yields. We also extended our developed methodology for the synthesis of 1,2,3-triazoles 
with different benzylic substituents linked with coumarins (Table 1, Entries 10-20). To our delight, all the 
reactions furnished the required products in good to excellent yields. Microwave irradiation proved to be 
superior in terms of yield as well as reaction time when compared to other standard conditions (Table 1, Entries 
1, 2 and 10). 
 
 
Table 1. Click chemistry reaction of alkyne intermediate 3 with various azides. 
Entry Azide Product (4a-t) Time Yieldb 
(%) 
1 
N3
O
 
OO O
NN
N
O
 
4a 
3 min 
6 hc 
18 hd 
97 
80 
86 
Article  J. Mex. Chem. Soc. 2020, 64(1) 
Regular Issue 
©2020, Sociedad Química de México 
ISSN-e 2594-0317 
 
62 
 
2 OH
N3
 
OO O
NN
N
OH
 
4b 
3 min 
6 hc 
18 hd 
95 
76 
85 
3 
N3
OH
 
OO O
NN
N
OH
 
4c 
3 min 
 
 
94 
 
 
4 
O
N3
 
OO O
NN
N
O
4d 
4 min 
 
92 
 
5 
O
N3
 
OO O
NN
N
O
4e 
4 min 
 
90 
 
6 
O
N
ClN3
 
OO O
NN
N
O
N
Cl
4f 
4 min 93 
7 
O N
Cl
N3
 
OO O
NN
N
O
N
Cl
4g 
4 min 94 
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8 
NH
OH
N3
 
OO O
NN
N
N
H
OH
 
4h 
3 min 97 
9 
N
H
ON3
 
OO O
NN
N
N
H
O
4i 
4 min 90 
10 N3
 
OO O
NN
N
 
4j 
3 min 
6 hc 
18 hd 
98 
83 
87 
11 N3
F  
OO O
NN
N
F  
4k 
3 min 
 
95 
 
12 N3
Cl  
OO O
NN
N
Cl  
4l 
3 min 
 
93 
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13 N3
NC  
OO O
NN
N
NC  
4m 
4 min 
 
92 
 
14 N3
O2N  
OO O
NN
N
O2N  
4n 
5 min 90 
15 N3
HO  
OO O
NN
N
HO  
4o 
3 min 
 
96 
 
16 N3
O  
OO O
NN
N
O  
4p 
3 min 
 
95 
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17 N3
H2N  
OO O
NN
N
H2N  
4q 
3 min 
 
98 
 
18 N3
NH  
OO O
NN
N
NH  
4r 
3 min 
 
98 
 
19 N3
 
OO O
NN
N
 
4s 
3 min 
 
96 
20 N3
 
OO O
NN
N
 
4t 
3 min 
 
95 
a Reaction conditions: Alkyne 3 (1 equiv.), Azide (1.3 equiv.), CuSO4.5H2O (0.1 equiv.), Sodium ascorbate (0.3 equiv.), 
t-BuOH/H2O (1:1), microwave irradiated at 90 °C. 
b Isolated yield. 
c Reaction carried out by conventional heating. 
d Reaction carried out at room temperature. 
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Biology 
Antimicrobial activity 
The clinical relevance of bacterial and fungal diseases has increased over the past 30 years due to an 
increasing population of immunocompromised patients who suffer from various illnesses. The development of 
multi drug resistance among pathogens could be a major reason for this increasing issue [37]. In view of these 
facts and stimulated by the profound activity profile of coumarins and 1,2,3-triazoles, we carried out the analysis 
of antibacterial and antifungal activities of the newly synthesized compounds 4a-t against two Gram-positive 
bacteria (Staphylococcus aureus ATCC 25923 and Bacillus subtilis ATCC 6633), two Gram-negative bacteria 
(Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922) and three fungi (Aspergillus flavus 
ATCC 9643, Chrysosporium keratinophilum ATCC90272 and Candida albicans MTCC 227). The results from 
the evaluation of antimicrobial activities in mg/mL concentration are illustrated in Table 1 and Table 2 of the 
Supplementary Information. Some of the tested compounds showed promising antibacterial activity when 
compared to the standard drug, Ciprofloxacin (See Table 1, Supplementary Information). The compounds 4f, 
4g, 4k, 4l, 4m and 4s showed promising activity when compared with the standard while the compounds 4b, 
4c, 4d, 4j, 4o and 4r failed to show any activity against the tested strains. All the other compounds displayed 
moderate to poor antibacterial activity.  
The minimum inhibitory concentration (MIC) of the more active compounds was determined by broth 
dilution method (Table 2). From the results, it was acknowledged that S. aureus (5 µg MIC) was the most 
susceptible, and E. coli (10 µg MIC), P. aeruginosa (10 µg MIC) and B. subtilis (10 µg MIC) were the most 
insensitive strain among all the bacteria used in this study. The compound 4k was found to be active against all 
the bacterial strains. The 4a, 4i, 4p (150 µg/mL MIC) and 4t (150 µg/mL MIC) showed weak activity as 
compared to 4f (10 µg/mL MIC), 4g (10 µg/mL MIC), 4k (10 µg/mL MIC), 4l (100 µg/mL MIC), 4m (100 
µg/mL MIC) and 4s (125 µg/mL MIC)  against E.coli (Table 2). In the last years, Gram-negative bacteria are 
frequently being reported to have developed multi drug resistance to many of the antibiotics that are currently 
available in the market of which E. coli is the most prominent [38,39]. This could be the plausible reason for 
the high MIC values for E. coli as compared to S. aureus. 
 
Table 2. Minimum inhibitory concentration of synthesized compounds for antibacterial activity. 
Compounds                            
in µg/mL 
Escherichiacoli Staphylococcusaureus Pseudomonasaeruginosa Bacillussubtilis 
4a --- 100 100 50 
4f 10 10 10 25 
4g 10 10 10 10 
4i --- 100 50 100 
4k 10 5 10 10 
4l 100 100 25 50 
4m 100 75 10 25 
4p 150 100 75 50 
4s 125 --- 75 50 
4t 150 100 75 100 
Ciprofloxacin 0.6 0.2 0.5 0.4 
 
 
The antifungal activity of the newly synthesized compounds was initially carried out in mill molar 
concentrations by taking Fluconazole as the standard (See Table 2, Supplementary Information). Among the 20 
synthesized organic compounds, only a few compounds inhibited the growth of most of the human pathogenic 
fungi tested. The fungal sensitivity varied according to the tested species. The compounds showed similar 
antifungal activities to one another. The minimum inhibitory concentration values for the antifungal activity of 
more active compounds are summarized in Table 3. Among the tested fungi, C. albicans was less sensitive 
when compared to the other fungal species. A. flavus and C. keratinophilm showed some differing responses to 
each organic compound. The compound 4n showed good activity when compared to the remaining compounds. 
On the other hand, all the newly synthesized organic compounds failed to show good and comparable activity 
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to that of the standard. The compounds 4b, 4c, 4d, 4e, 4h, 4j, 4o and 4r failed to show any activity towards the 
panel of fungal pathogens. 
 
Table 3. Minimum inhibitory concentration of synthesized compounds for antifungal activity. 
Compounds                           
in µg/mL 
Aspergillus flavus Chrysosporium keratinophilum Candida albicans 
4a 300 350 400 
4f 300 250 350 
4g >500 >500 >500 
4i >500 >500 >500 
4k 250 200 200 
4l >500 >500 >500 
4m >500 >500 >500 
4n 200 150 150 
4p >500 >500 >500 
4q >500 >500 >500 
4s 300 250 350 
4t 350 300 400 
Fluconazole 10 20 30 
 
 
Structure-activity relationships 
The presence of electron withdrawing fluoro group in 4k is presumed to be the sole reason for the 
comparable antibacterial activity of that compound. The presence of heterocyclic ring having a chloro 
substituent was assumed to be beneficial for the enhanced activity of compounds 4f and 4g. The electron 
withdrawing groups are expected to increase the lipophilicity and thereby enhance the cell permeability of the 
molecule and hence improved its potency [40]. In general, it can be summarized that in the present study, the 
presence of ring substitution with an electron withdrawing group and heterocyclic group at position 1 of 1,2,3-
triazoles linked with coumarins is an essential feature for the antimicrobial effect of the synthesized compounds. 
 
Antioxidant activity 
The DPPH procedure is one of the most effective methods for evaluating the concentration of radical 
scavenging materials as it does not have to be generated prior to analysis [41]. DPPH radical scavenging activity 
evaluation is a rapid and convenient assay for screening the antioxidant activities of products and has been 
successfully applied for the evaluation of radical scavenging activity of newly synthesized coumarin derivatives 
[42] as they possess an extended p-conjugated system. Owing to these observations, we directed our work 
towards the evaluation of antioxidant activity of the synthesized compounds 4a-t by DPPH assay. 
 
Table 4. Determination of antioxidant activity of the synthesized compounds. 
Entry Compound % Inhibition at 100 µg Concentration 
1 4a 54.2 
2 4b 66.1 
3 4c 68.3 
4 4d 36.4 
5 4e 31.4 
6 4f 26.1 
7 4g -- 
8 4h 74.2 
9 4i 41.8 
10 4j -- 
11 4k -- 
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12 4l 28.1 
13 4m 30.7 
14 4n 56.3 
15 4o 61.8 
16 4p -- 
17 4q 73.5 
18 4r 29.4 
19 4s -- 
20 4t -- 
21 Standard (BHT) 88.6 
 
 
The synthesized compounds were subjected to antioxidant screening by taking Butylated 
hydroxytoluene (BHT) as the standard and our results are summarized in Table 4. In this assay, the standard 
BHT showed a strong scavenging activity, while the compounds 4b (66.1 %), 4h (74.2 %), 4o (61.8 %), 4q 
(73.5 %) and 4c (68.3 %) displayed a comparable activity (Fig 2). Unfortunately, the compounds 4g, 4j, 4k, 4p, 
4s and 4t didn’t exhibit any activity when compared with the standard and hence are considered as inactive. All 
the other compounds also showed significant scavenging activity, but demanded higher concentrations of the 
compounds. 
 
 
Fig 2: The DPPH• scavenging activity of synthesized compounds in comparison with the standard. 
 
 
 
Structure-activity relationships 
The results of antioxidant screening revealed that the presence of electron donating ring systems 
attached to the position 1 of 1,2,3-triazole ring linked with coumarins is an indispensable characteristic for their 
radical scavenging activity. The hydrophilic electron-donating groups are expected to facilitate the stabilization 
of the oxygen-centered radical and reduce the O–H bond dissociation enthalpy (BDE), thereby increasing the 
radical scavenging activity by hydrogen abstraction [43,44]. This could be the plausible reason for the superior 
activity of compounds 4b, 4h, 4o, 4q and 4c to that of the other synthesized molecules. 
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Molecular docking studies 
The Gyrase enzyme relieves strain while the double-stranded DNA is being unwound by helicase 
[45,46]. It is an essential enzyme in all bacteria but absent in higher eukaryotes, hence making it an interesting 
antibacterial target [47-50]. Furthermore, the mode of antibacterial action of Ciprofloxacin is by significantly 
inhibiting the gyrase enzyme. Hence, the molecular docking studies of the active compounds with gyrase were 
carried out and reported. Stimulated by the comparable antibacterial activity of some of the synthesized 
compounds (4f, 4g, 4k and 4l) with the standard as per the in vivo results, it was thought worthy to substantiate 
those results by performing the molecular docking studies or in silico studies. The comparative docking of 
receptor gyrase with 4f, 4g, 4k, 4l and the standard, Ciprofloxacin, exhibited good affinity. They established 
hydrogen bonding with one or more amino acids in the receptor active pocket as represented in Table 5.  
 
Table 5. Binding affinity (kcal/mol), H-bonds, H-bond length and H-bond formation of the standard and the 
selected molecules after in silico docking. 
Ligand Affinity 
(kcal/mol) 
H-Bonds H-Bond 
Length 
(Å) 
H-Bond Between Hydrophobic 
interactions 
4f -6.9 4 2.80 4f:N3::Glu435:OE2 Phe1123, 
Asp437, Gly436, 
Gly459, Lys460, 
His1081 
3.04 4f:N :: Gly1082:N 
3.09 4f:O4 :: Ser1085:OG 
3.14 4f:N2 :: Glu435:O 
4g -6.3 3 2.83 4g:N4::Glu435:OE2 Asp512, Ile516, 
His1081, 
Gly1082, 
Arg1122, 
Phe1123, Gly436 
2.96 4g:O3::Asp437:N 
3.17 4g:O3::Ser438:N 
4k -7.2 4 2.99 4k:O3::Ser1085:OG Ile516, 
Lys460, Gly436, 
Gly459, 
Phe1123, 
His1081 
3.12 4k:O3::Gly1082:N 
3.12 4k:N2::Glu435:O 
3.15 4k:E::Arg1122:NH1 
4l -6.1 1 2.90 4l:O3::Gly459:N Arg458, Asp437, 
Gly436, 
Arg1122, 
Phe1123,  
Glu435, Asp512, 
Asp510 
Ciprofloxacin -6.2 2 2.83 Cipr:O3::Asp510:OD2 Gly459, Asp437, 
Gly436, 
Phe1123, 
Asp512, 3.02 Cipr:O2::His1081:ND1 
 
The 2D representation of the synthesized ligands 4f, 4g, 4k, 4l and the standard Ciprofloxacin is 
depicted in Figure 3. The compound 4k was found to be the best of all the molecules taken under investigation 
as it possessed significant hydrogen bonding as well as hydrophobic interactions. For 4k (Fig 3), hydrophobic 
contacts were seen with six different residues and four H-bonds were formed with various amino acids (Table 
5). The standard Ciprofloxacin (Fig 3) represented hydrophobic contacts with five different residues, later a 
total of two H-bonds were formed with various amino acids (Table 5). In all the cases of the 2D representation, 
ligands are highlighted in purple colour. The set of conserved residues that are commonly involved in interaction 
with the ligands and Ciprofloxacin are encircled with red colour. 
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Fig 3. 2D representation of the interaction of 4f, 4g, 4k, 4l and Ciprofloxacin with 2XCT (gyrase) 
 
 
 
Based upon the obtained affinity, the best of the synthesized ligands i.e., 4k along with the standard 
Ciprofloxacin was subjected to 3D protein-ligand interaction analysis. Figure 4 represents the further 
extrapolation of binding conformation of 4k and Ciprofloxacin. Figures 4 (A) and (B) represent the 3D 
interaction of 4k and Ciprofloxacin respectively with gyrase by using educational version of PyMol [51]. The 
ligands are represented in green colour, H-bonds with their respective distances are represented with yellow 
colour, and the interacting residues are represented in ball and stick model representation. 
Article  J. Mex. Chem. Soc. 2020, 64(1) 
Regular Issue 
©2020, Sociedad Química de México 
ISSN-e 2594-0317 
 
71 
 
 
Fig 4. (A) 3D representation of the interaction of 4k and (B) Ciprofloxacin with 2XCT (gyrase) 
 
 
 
In the present study, 4k was identified to be the best antibacterial agent among all the synthesized 
compounds which could be attributed to the electron withdrawing character of fluorine atom as well as the 
ability of the molecule to form significant hydrogen bonding. 
 
 
Conclusion 
 
We have achieved a rapid, facile and efficient access for the synthesis of an array of 1,2,3-triazoles 
linked with coumarins via click chemistry and evaluated their antimicrobial and antioxidant properties. 
Microwave irradiation proved to be superior to other conventional methods for this synthetic methodology in 
terms of yield as well as reaction time. The compounds 4k and 4g exhibited promising antibacterial activity 
when compared with Ciprofloxacin against all the tested bacteria. The in silico docking studies of the more 
active antibacterials were carried out against the gyrase enzyme and found that 4k possessed significant 
hydrogen bonding and hydrophobic interactions which could also be the plausible reason for its improved 
potency along with the presence of electron withdrawing fluoro group. The compound 4n displayed better 
antifungal activity when compared to other synthesized compounds but were not promising when compared 
with the standard, flucanazole. The compounds 4h and 4q showed comparable antioxidant activity with the 
standard, BHT, presumably due to the presence of electron donating substituents. The present study paved the 
way for the synthesis of various coumarin analogues with significant pharmacological properties and further 
derivatization and lead optimization are in progress. 
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